In News

Follow this topic

Bookmark

Record learning outcomes

The Medicines and Healthcare products Regulatory Agency (MHRA) has recalled all stocks of domperidone, following the reclassification of the drug from a 'P' medicine to a prescription only medicine (POM). The announcement follows a review by the European Medicines Agency (EMA), which found that domperidone is associated with a small increased risk of potentially life-threatening effects on the heart. The drug, which is found in Motilium 10 and Motilium Instants, is used to treat the symptoms of nausea and vomiting.

Dr Sarah Branch, deputy director of the MHRA's Vigilance and Risk Management of Medicines Division, said: €Patient safety is our priority €“ we continually monitor the safety of medicines after they are licensed so that we can take action if the need arises.€ She added that patients taking domperidone without a prescription should speak to their doctor or pharmacist.